Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

C135-LS/C144-LS · BMS-986414, C135-LS

Monoclonal antibody · Acts on SARS-CoV-2 spike protein

Phase 2/3 Most advanced trial (none active)
1 Registered trials

What is C135-LS/C144-LS?

C135-LS/C144-LS is a pair of antibodies given subcutaneously as one combined dose of four injections.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BMS-986414, C135-LS
Drug type
Monoclonal antibody
Targets
SARS-CoV-2 spike protein
Mechanism
Acts on SARS-CoV-2 spike protein
Therapy area
Infectious disease
In trials of
SABS
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
SC4RQX96VW

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04518410 Phase 2/3 Coronavirus Completed SABS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CoronavirusCovid19

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.